Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. Esperion brought the first ATP Citrate Lyase (ACLY) inhibitor to market and continues to leverage its deep expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide.

The company offers three FDA-approved cardiovascular disease therapies including two oral treatments containing an ACLY Inhibitor and a nasal spray loop diuretic.

With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities.

The Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for primary sclerosing cholangitis and renal diseases.